Kona Medical — Pioneering Non-Invasive Hypertension Treatment in LATAM

Kona Medical developed Surround Sound®, a non-invasive externally focused ultrasound system for renal denervation to treat resistant hypertension. bioaccess® managed their first clinical studies in Latin America.

Study facts

Key metrics

The challenge

Resistant hypertension affects 10–15% of hypertensive patients globally. Kona Medical's non-invasive approach could eliminate the need for catheter-based procedures, but the company needed early human feasibility data to differentiate from catheter-based competitors and validate their ultrasound-guided approach.

bioaccess® solution

bioaccess® coordinated early feasibility studies in Colombia with hypertension specialists, managing patient screening, treatment delivery, and ambulatory blood pressure monitoring follow-up to demonstrate the feasibility and safety of the non-invasive renal denervation approach.

Results

Frequently asked

What did bioaccess® do for Kona Medical?
bioaccess® coordinated early feasibility studies in Colombia with hypertension specialists, managing patient screening, treatment delivery, and ambulatory blood pressure monitoring follow-up to demonstrate the feasibility and safety of the non-invasive renal denervation approach.
Where was the Kona Medical Early Feasibility Study (EFS) study run?
The Kona Medical Early Feasibility Study (EFS) study was executed in Colombia by bioaccess® in the cardiovascular / hypertension area.
What was the outcome of the Kona Medical study?
Reported outcomes for Kona Medical's device: Early feasibility study completed with promising blood pressure reductions; Non-invasive approach validated as safe in human subjects; Ambulatory blood pressure data collected per protocol.

Run a similar trial: Clinical trials in Colombia

First-in-Human Clinical Trials pillar · LATAM FIH Benchmarks 2026 · ← All case studies · Contact bioaccess®